Search Results 171-180 of 15179 for TNF
Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5 half-lives of randomization. Participating Mayo Clinic locations.
Immunosuppressive mediations (steroids, tumor necrosis factor (TNF)-inhibitors, azathioprine, etc.) within the past 6 weeks; Active or chronic infection with ...
... tumor necrosis factor (TNF)-α agents, integrin inhibitor. Exclusion Criteria: Participant with current diagnosis of Crohn's disease (CD) or diagnosis of ...
... TNF. Subjects receiving any treatment(s) for UC are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period ...
Tumor necrosis factor receptor superfamily biology in cancer; Identification of novel drug targets, high-throughput screening for drug discovery and ...
The Sensitizing Effects of TRAF2 Deficiency on TNF- and IFNy-Induced Cancer Cell Death; Utilizing Molecular Dynamics Simulations to Characterize Pathogenic ...
... tumor necrosis factor-alpha (TNF-α) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula). France ...
... TNF. Subjects who have had an inadequate response to sulfasalazine or mesalamine should have also failed at least 1 other conventional treatment such as ...
Paradoxical autoimmune side effects of tumor necrosis factor-alpha inhibitors, including psoriasis, lupus and vasculitis. Significance to patient care. Dr ...
This includes anti-tumor necrosis factor-alpha (TNF-α) and anti-integrin therapy, anti- interleukin (IL) 12/23, thiopurines and other immunomodulators ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.